CMR Molecular Imaging
CMR Molecular Imaging is a privately-held medical device company, founded in 1973 in Carlsbad, California, that develops high-resolution PET scanners for visualization of small body parts, serving hospital-based neurology and diagnostic imaging applications.
- Company typePrivate
- Founded1973
- HeadquartersCarlsbad, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CMR Molecular Imaging does
CMR Molecular Imaging is a privately-held medical imaging company headquartered in Carlsbad, California, founded in 1973. The company provides high-resolution PET (Positron Emission Tomography) scanners engineered for exceptional visualization of small body parts, positioning it within the broader functional brain imaging system market. According to available market context, this market is projected to grow from USD 2,180.7 million in 2025 to USD 3,420.6 million by 2035 at a 4.5% CAGR, with fMRI technology leading at 49.7% of market share. CMR's served end-user base skews to hospitals, which command 52.7% of functional brain imaging demand, with neurology applications representing 44.9% of the market by use case and being driven by needs in neurological and psychiatric disorder diagnosis and monitoring.
The company's core technical offering is a dedicated high-resolution PET scanner optimized for small-anatomy imaging, distinguishing it from general-purpose PET/CT systems sold by large incumbents. In October 2017, CMR expanded its technology footprint via the acquisition of Gamma Medica, a molecular imaging specialist, for an undisclosed amount. The company's website (cmr-naviscan.com) currently serves only as a verification page, and no detailed product specifications, pricing, distribution model, headcount, funding history, or financial disclosures are available in the source material.
Revenue mechanics, go-to-market channels, and customer concentration are not documented. The company appears to operate as a specialty OEM selling capital equipment into hospital radiology and nuclear medicine departments, likely through a direct sales model and potentially distributor relationships, but this is inferred rather than confirmed. The most material observable fact is the long operating history (over 50 years), the niche product positioning around high-resolution small-body-part PET, and the 2017 Gamma Medica acquisition, against an otherwise sparse public information profile.
CMR Molecular Imaging firmographics
Firmographics- Name
- CMR Molecular Imaging
- Website
- https://cmr-naviscan.com
- Company type
- Private
- Founded year
- 1973
- Headcount range
- 11–50 employees
- Short description
- CMR Molecular Imaging is a privately-held medical device company, founded in 1973 in Carlsbad, California, that develops high-resolution PET scanners for visualization of small body parts, serving hospital-based neurology and diagnostic imaging applications.
- Ownership category
- akta.pro rank
CMR Molecular Imaging industry classification
Industry- Product category
- Medical Imaging Equipment
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE)
Keywords
Where CMR Molecular Imaging is headquartered
LocationHeadquarters
- HQ city
- Carlsbad
- HQ country
- United States
- HQ region
- North America
Markets served
CMR Molecular Imaging business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel
CMR Molecular Imaging product offering
Product offeringCore offering
CMR Molecular Imaging provides a high-resolution PET scanner that delivers exceptional visualization of small body parts, serving as a functional brain imaging system for neurological and psychiatric disorder diagnosis. The company's offering is positioned within the functional brain imaging system market, which is targeted primarily at hospital end-users and neurology applications.
Product overview
No product information available. The source data does not contain specific product details for CMR Molecular Imaging. The available webpage content consists of a verification/loading page (cmr-naviscan.com), and the news article provides only general market context for the functional brain imaging system market without detailing CMR Molecular Imaging's specific product portfolio.
Differentiator
Problem solved
Functional benefit
Products and services
- High-Resolution PET Scanner
Companies that use CMR Molecular Imaging
Customer profileSegments2 records
Ideal customer profiles1 record
CMR Molecular Imaging technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CMR Molecular Imaging partnerships and signals
Strategic signalScale indicators1 record
Recent moves1 record
Expansion highlights3 records
CMR Molecular Imaging competitors and assessment
Company assessmentBroad incumbents
- GE HealthCare: GE HealthCare is a global medical imaging OEM with a broad portfolio that includes PET/CT systems. It is comparable to CMR Molecular Imaging as a much larger incumbent in the molecular imaging equipment market, competing for hospital capital budgets in nuclear medicine.
- Siemens Healthineers: Siemens Healthineers manufactures a full line of diagnostic imaging systems including PET, SPECT, and hybrid PET/CT. It competes with CMR Molecular Imaging across molecular imaging hardware, particularly in hospital and specialty imaging deployments.
- Philips Healthcare: Philips Healthcare offers a broad diagnostic imaging portfolio including PET and hybrid molecular imaging systems. As a full-suite imaging OEM, it competes with CMR Molecular Imaging for the same hospital and specialty clinic capital purchasing decisions.
- Canon Medical Systems: Canon Medical Systems produces diagnostic imaging equipment including PET/CT systems. It is a comparable broad-line imaging incumbent that competes with CMR Molecular Imaging in molecular imaging capital sales.
Emerging players
- United Imaging Healthcare: United Imaging Healthcare is a China-based imaging OEM that has rapidly expanded into PET/CT and other molecular imaging modalities. It is comparable to CMR Molecular Imaging as a growing entrant in PET imaging equipment targeting hospital customers.
- Cubresa: Cubresa develops preclinical PET imaging systems for research and translational applications. It is comparable to CMR Molecular Imaging as a smaller, focused player in the high-resolution, small-specimen PET imaging niche.
- MR Solutions: MR Solutions manufactures preclinical MRI and PET imaging systems for research institutions. It is a comparable emerging player serving the same high-resolution, small-animal and dedicated molecular imaging markets as CMR Molecular Imaging.
Direct peers
- Bruker Corporation: Bruker manufactures preclinical and molecular imaging systems, including PET, SPECT, and MRI for research and specialty clinical use. It is highly comparable to CMR Molecular Imaging's specialty/preclinical PET focus, particularly in the small-animal and dedicated-organ imaging segments served via the Gamma Medica lineage.
- Mediso Medical Imaging Systems: Mediso makes preclinical and clinical molecular imaging systems including dedicated PET and SPECT scanners. It directly competes with CMR Molecular Imaging in small-animal, organ-dedicated, and specialty clinical PET imaging.
- Positron Corporation: Positron Corporation focuses on PET and nuclear medicine imaging equipment for cardiac and specialty clinical applications. It is a direct peer to CMR Molecular Imaging as a small, focused PET equipment vendor targeting niche clinical imaging indications.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
CMR Molecular Imaging social profiles
Digital presenceCMR Molecular Imaging financial estimates
Financial estimateRevenue estimate
Valuation estimate
CMR Molecular Imaging leadership team
Management profileNumber of profiles
Profiles1 record
CMR Molecular Imaging funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CMR Molecular Imaging M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CMR Molecular Imaging
What does CMR Molecular Imaging do?
CMR Molecular Imaging provides a high-resolution PET scanner that delivers exceptional visualization of small body parts, serving as a functional brain imaging system for neurological and psychiatric disorder diagnosis. The company's offering is positioned within the functional brain imaging system market, which is targeted primarily at hospital end-users and neurology applications.
When was CMR Molecular Imaging founded?
CMR Molecular Imaging was founded in 1973. It employs 11 to 50 people.
Where is CMR Molecular Imaging based?
CMR Molecular Imaging is headquartered in Carlsbad, United States, in the North America region.
Who are CMR Molecular Imaging's main competitors?
Broad incumbents on record are GE HealthCare, Siemens Healthineers, Philips Healthcare and Canon Medical Systems. Emerging players are United Imaging Healthcare, Cubresa and MR Solutions. Direct peers are Bruker Corporation, Mediso Medical Imaging Systems and Positron Corporation.
Does CMR Molecular Imaging have an API?
No public API is recorded for CMR Molecular Imaging.
What industry is CMR Molecular Imaging in?
CMR Molecular Imaging's product category is Medical Imaging Equipment. Its primary akta.pro industry code is HLAHABAE, Nuclear Medicine & Molecular Imaging (SPECT/PET). Its NAICS code is 33451 and its SIC code is 3841.